The state of the melatonin-associated hormonal system in children with overweight

Main Article Content

T.V. Sorokman
O.V. Makarova
D.I. Kolesnik


Background. Overweight (OW) may be the first step to obesity. The mechanisms underlying the pathogenesis of obesity and chronic diseases associated with it are being studied to combat this global pandemic. In this context, dysfunction of adipose tissue is considered, which manifests itself in the form of changes in the profile of adipokines, the secretion of some of them is under circadian control. This regulation may, at least, be partially mediated by melatonin. Objective: to study the state of the melatonin-associated hormonal system in children with OW and normal weight (NW). Materials and methods. A one-time epidemiological survey of the children population aged 7–18 years was conducted during preventive examinations in schools in Chernivtsi and Chernivtsi region (936 people). Primary screening included questioning, anthropometry, and assessment of physical development. A total of 60 people with OW were selected from 936 individuals for a detailed study. The comparison group included 55 healthy subjects with NW. Diagnosis of OW was established if body mass index was greater than 85th percentile, but less than 95th percentile according to age-sex nomograms. NW was diagnosed with body mass index values ranging from 5th to 84th percentiles. For evaluation of serum concentrations of melatonin, adiponectin, leptin, resistin, and omentin-1, commercially available immunoassay kits for the Model 680 Microplate Reader were used. Statistical data analysis was performed using the Statistica 10.0 application package. Results. Among those with OW, boys were dominant — 32 (53.3 %). OW was most often registered among boys over 17 years of age (59.4 %) and girls aged 15–16 years (64.2 %, pφ < 0.05). According to the study, children with OW have significantly lower melatonin levels and imbalance of melatonin-associated hormones. Leptin and resistin indices were within the reference values in both groups and in all age groups, the level of adiponectin was statistically significantly lower in patients with OW, and the level of omentin-1 tended to decrease. Hormonal imbalance deepens with increasing body mass. Conclusions. It has been established that children with оverweight have significantly lower melatonin levels and imbalance of melatonin-associated hormones.

Article Details

How to Cite
Sorokman, T., O. Makarova, and D. Kolesnik. “The State of the Melatonin-Associated Hormonal System in Children With Overweight”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 15, no. 6, Dec. 2019, pp. 469-74, doi:10.22141/2224-0721.15.6.2019.185409.
Original Researches


Ball GDC, Savu A, Kaul P. Changes in the prevalence of overweight, obesity, and severe obesity between 2010 and 2017 in preschoolers: A population-based study. Pediatr Obes. 2019 Nov;14(11):e12561. doi: 10.1111/ijpo.12561.

Javed A, Jumean M, Murad MH, et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity in children and adolescents: a systematic review and meta-analysis. Pediatr Obes. 2015 Jun;10(3):234-44. doi: 10.1111/ijpo.242. 

Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011 Aug 27;378(9793):804-14. doi: 10.1016/S0140-6736(11)60813-1. 

Psaltopoulou T, Tzanninis S, Ntanasis-Stathopoulos I, et al. Prevention and treatment of childhood and adolescent obesity: a systematic review of meta-analyses. World J Pediatr. 2019 Aug;15(4):350-381. doi: 10.1007/s12519-019-00266-y.

Trayhurn P. Adipocyte biology. Obes Rev. 2007 Mar;8 Suppl 1:41-4. doi: 10.1111/j.1467-789X.2007.00316.x. 

Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004 Jun;89(6):2548-56. doi: 10.1210/jc.2004-0395.

Aguilar-Valles A, Inoue W, Rummel C, Luheshi GN. Obesity, adipokines and neuroinflammation. Neuropharmacology. 2015 Sep;96(Pt A):124-34. doi: 10.1016/j.neuropharm.2014.12.023.

The American Association of Clinical Endocrinologists, American College of Endocrinology. 2014. Available from:

De Ferranti S, Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem. 2008 Jun;54(6):945-55. doi: 10.1373/clinchem.2007.100156. 

Leal Vde O, Mafra D. Adipokines in obesity. Clin Chim Acta. 2013 Apr 18;419:87-94. doi: 10.1016/j.cca.2013.02.003. 

Ray I, Mahata SK, De RK. Obesity: An Immunometabolic Perspective. Front Endocrinol (Lausanne). 2016 Dec 12;7:157. doi: 10.3389/fendo.2016.00157. 

Vincent HK, Taylor AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond). 2006 Mar;30(3):400-18. doi: 10.1038/sj.ijo.0803177. 

Gómez-Santos C, Gómez-Abellán P, Madrid JA, et al. Circadian rhythm of clock genes in human adipose explants. Obesity (Silver Spring). 2009 Aug;17(8):1481-5. doi: 10.1038/oby.2009.164.

Johnston JD. Adipose circadian rhythms: translating cellular and animal studies to human physiology. Mol Cell Endocrinol. 2012 Feb 5;349(1):45-50. doi: 10.1016/j.mce.2011.05.008. 

Reiter RJ, Tan DX, Galano A. Melatonin: exceeding expectations. Physiology (Bethesda). 2014 Sep;29(5):325-33. doi: 10.1152/physiol.00011.2014.

Hardeland R, Madrid JA, Tan DX, Reiter RJ. Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J Pineal Res. 2012 Mar;52(2):139-66. doi: 10.1111/j.1600-079X.2011.00934.x. 

Bonnefont–Rousselot D. Obesity and oxidative stress: potential roles of melatonin as antioxidant and metabolic regulator. Endocr Metab Immune Disord Drug Targets. 2014;14(3):159-68. doi: 10.2174/1871530314666140604151452.

Cipolla-Neto J, Amaral FG, Afeche SC, Tan DX, Reiter RJ. Melatonin, energy metabolism, and obesity: a review. J Pineal Res. 2014 May;56(4):371-81. doi: 10.1111/jpi.12137. 

Walecka-Kapica E, Chojnacki J, Stępień A, Wachowska-Kelly P, Klupińska G, Chojnacki C. Melatonin and female hormone secretion in postmenopausal overweight women. Int J Mol Sci. 2015 Jan 5;16(1):1030-42. doi: 10.3390/ijms16011030.

Bonnefont-Rousselot D. Obesity and oxidative stress: potential roles of melatonin as antioxidant and metabolic regulator. Endocr Metab Immune Disord Drug Targets. 2014;14(3):159-68. doi: 10.2174/1871530314666140604151452.

de Luxán-Delgado B, Caballero B, Potes Y, et al. Melatonin administration decreases adipogenesis in the liver of ob/ob mice through autophagy modulation. J Pineal Res. 2014 Mar;56(2):126-33. doi: 10.1111/jpi.12104.

Tanofsky-Kraff M, Yanovski SZ, Wilfley DE, Marmarosh C, Morgan CM, Yanovski JA. Eating-disordered behaviors, body fat, and psychopathology in overweight and normal-weight children. J Consult Clin Psychol. 2004 Feb;72(1):53-61. doi: 10.1037/0022-006X.72.1.53.

Mirzayi K, Hossein-Nejad A, Shamari M, Shahbazi S. Evidence of the role of ANGPTL6 in resting metabolic rate and its possible application in the treatment of obesity. Minerva Endocrinol. 2011 Mar;36(1):13-21.

Schoppen S, Riestra P, García-Anguita A, et al. Leptin and adiponectin levels in pubertal children: relationship with anthropometric variables and body composition. Clin Chem Lab Med. 2010 May;48(5):707-11. doi: 10.1515/CCLM.2010.142.

Shibata R, Ouchi N, Takahashi R, et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr. 2012 Jul 26;4(1):37. doi: 10.1186/1758-5996-4-37.

Wanders D, Plaisance EP, Judd RL. Lipid-lowering drugs and circulating adiponectin. Vitam Horm. 2012;90:341-74. doi: 10.1016/B978-0-12-398313-8.00013-0.

Halabis M, Dziedzic M, Warchulinska J, Kaznowska-Bystryk I, Solski J. Omentin – a new adipokine with many roles to play. Current Issues in Pharmacy and Medical Sciences. 2015 Sep;28(3): 176-180. doi: 10.1515/cipms-2015-0067.

Hossein-nezhad A, Mirzaei K, Alatab S, Ahmadivand Z, Najmafshar A. Circulating Omentin-1 in Obesity and Metabolic Syndrome Status Compared to Control Subjects. Endocrinol Metabol Syndrome. 2012;S1:008. doi:10.4172/2161-1017.S1-008.

Most read articles by the same author(s)

1 2 3 > >>